The new collaboration will introduce the specialty care product of pharma& (zr pharma& GmbH) into Hong Kong and Macau markets, while expanding DKSH Business Unit Healthcare’s portfolio of high-quality brands.
Hong Kong, July 20, 2022 – DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, and pharma& (zr pharma& GmbH), an Austrian pharmaceutical multinational, have jointly announced their exclusive partnership.
DKSH will provide distribution, marketing and sales services as well as regulatory services to pharma& for their newly acquired specialty care product in Hong Kong, called Pegasys®. Special emphasis will be placed on expanding its channel network. The agreement covers both Hong Kong and Macau.
Pegasys® (Peginterferon alfa 2a) is used to treat patients suffering from Chronic Hepatitis B (CHB) and Chronic Hepatitis C (CHC). The medicine can be administered as a monotherapy or in combination with other medicinal products.
Mr. Kaustav Chatterjee, Commercial Operations Director, pharma&, said: “pharma& is committed to the well-being of our niche patient populations globally and to ensuring that Pegasys® continues to be provided to those in need. We are excited to partner with DKSH Hong Kong for Pegasys®, as we believe that they have the knowledge and the experience to serve these patient populations and the healthcare professionals who have known and trusted Pegasys® for many years.”
Wai Ting Fong, Head of Management and Vice President, Healthcare, DKSH Hong Kong, equally welcomed the partnership: “We are delighted to partner with pharma& to bring niche and original products to patients in Hong Kong and Macau. With our in-depth experience and our broad network of healthcare professionals in these two markets, we are confident to effectively support pharma&’s expansion within and beyond Asia.”